Potential risk of perioperative thromboembolism in patients with antiphospholipid syndrome who undergo transcatheter aortic valve implantation: A case series

2020 ◽  
Author(s):  
Tomoya Hoshi ◽  
Daigo Hiraya ◽  
Akira Sato ◽  
Masaki Ieda
Keyword(s):  
Aortic Valve ◽  
Antiphospholipid Syndrome ◽  
Transcatheter Aortic Valve Implantation ◽  
Potential Risk ◽  
Case Series ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Anesthesia Management for Transapical Transcatheter Aortic Valve Implantation: A Case Series

2009 ◽  
Vol 23 (3) ◽  
pp. 286-291 ◽  
Author(s):  
Jens Fassl ◽  
Thomas Walther ◽  
Heinrich Volker Groesdonk ◽  
Joerg Kempfert ◽  
Michael Andrew Borger ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Case Series ◽  
Anesthesia Management ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals Leaflet thrombosis after valve-in-valve transcatheter aortic valve implantation: a case series

2020 ◽  
Vol 4 (4) ◽  
pp. 1-6 ◽  
Author(s):  
Dincer Aktuerk ◽  
Saeed Mirsadraee ◽  
Cesare Quarto ◽  
Simon Davies ◽  
Alison Duncan
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Oral Anticoagulation ◽  
Anticoagulation Therapy ◽  
Case Series ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve ◽  
Valve In Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Abstract Background Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in degenerated surgical aortic valve replacement (SAVR) is an alternative to redo-SAVR. However, reports on leaflet thrombosis following ViV-TAVI are emerging and subclinical thrombosis has gained recent attention. Although the incidence of transcatheter heart valve (THV) thrombosis after TAVI for native aortic valve disease is low, current imaging studies suggest the incidence of subclinical THV thrombosis may be significantly higher. While anticoagulation strategies for THV patients for native aortic stenosis presenting with symptomatic obstructive thrombosis has been described, the optimal management and anticoagulation therapy of patients with THV thrombosis following ViV-TAVI are less evident. Case summary We report a case series of three patients presenting with early and late THV thrombosis after ViV-TAVI. Two patients presented clinically on single antiplatelet therapy and one patient presented with subclinical valve thrombosis whilst taking a non-vitamin K oral anticoagulation agent. Discussion Leaflet thrombosis after ViV-TAVI is an important cause of THV degeneration and may present subclinically. Imaging modalities such as serial transthoracic echocardiograms and multidetector computerized tomography aid diagnosis and guide management. Patient-individualized risk- vs. -benefit prophylactic post-procedural oral anticoagulation may be indicated.

Sign in / Sign up

Export Citation Format

Share Document